Document Detail

Abciximab combined with half-dose reteplase has beneficial effects on inflammatory myocardial response in patients with myocardial infarction.
MedLine Citation:
PMID:  19786940     Owner:  NLM     Status:  MEDLINE    
In patients with ST-segment elevation myocardial infarction (STEMI), myocardial reperfusion is associated with an inflammatory response leading to adverse effects on further myocardial damage. Therefore, we investigated the effects of the thrombolytic regimen with half-dose reteplase (r-PA) combined with abciximab on different cytokines involved in the local and systemic inflammatory scenario in STEMI patients. Thirty-eight STEMI patients were enrolled in this study. We investigated the effects of the regimen with half-dose r-PA plus abciximab versus full-dose r-PA on interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), MCP-1 and tumor necrosis factor-alpha (TNF-alpha) up to 48 h after the start of therapy. The full-dose r-PA group had a significant IL-6 increase after 48 h compared with the combination group. Furthermore, the full-dose r-PA group showed a marked increase of IL-10 (up to 3 h after) compared with a 41% IL-10 decrease in the combination group. MCP-1 decreased significantly after 3 h in the combination group compared with patients on r-PA therapy only. The combination group showed a nonsignificant increase in IL-8 within the first 6 h. There were no differences in TNF-alpha levels between the two infarct groups. In vivo, the investigated combined thrombolytic regimen consisting of half-dose r-PA plus abciximab causes less of an IL-6 increase and marked decreases in IL-10 and MCP-1 in STEMI patients compared with the pure r-PA thrombolytic regimen. This observation suggests that besides the known beneficial effects on systemic coagulation and leukocyte-platelet aggregates, this regimen may exert a favorable influence on myocardial tissue damage and thus on cardiac repair following myocardial infarction.
Sebastian Szabo; Diana Etzel; Thomas Walter; Silke Kazmaier; Thomas Oikonomopoulos; Roger Marx; Hans Martin Hoffmeister
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  20     ISSN:  1473-5733     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-09-29     Completed Date:  2009-12-08     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  England    
Other Details:
Languages:  eng     Pagination:  129-33     Citation Subset:  IM    
Department of Internal Medicine II, Klinik für Kardiologie, Städtisches Klinikum, Gotenstrasse 1, Solingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage*
Anticoagulants / administration & dosage*
Cytokines / blood
Dose-Response Relationship, Drug
Drug Therapy, Combination
Fibrinolytic Agents / administration & dosage*
Immunoglobulin Fab Fragments / administration & dosage*
Inflammation / blood,  drug therapy
Inflammation Mediators / blood
Middle Aged
Myocardial Infarction / blood,  drug therapy*
Recombinant Proteins / administration & dosage
Regeneration / drug effects*
Tissue Plasminogen Activator / administration & dosage*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Anticoagulants; 0/Cytokines; 0/Fibrinolytic Agents; 0/Immunoglobulin Fab Fragments; 0/Inflammation Mediators; 0/Recombinant Proteins; 133652-38-7/reteplase; EC Plasminogen Activator; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Polymorphisms in exons 6 and 7 of the ABO locus and their association with venous thrombosis in youn...
Next Document:  Association of inherited thrombophilia with embryonic and postembryonic recurrent pregnancy loss.